December 19, 2016 / 12:30 PM / 8 months ago

BRIEF-Akcea and Ionis announce positive results from study of Volanesorsen

Dec 19 (Reuters) - Ionis Pharmaceuticals Inc

* Akcea and Ionis announce positive results from compass phase 3 study of Volanesorsen

* Akcea plans to have top-line data from pivotal approach study in patients with FCS in Q1 of 2017

* For primary endpoint of study, volanesorsen-treated patients achieved a statistically significant mean reduction in triglycerides Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below